Cargando…
LncRNA POU3F3 Contributes to Dacarbazine Resistance of Human Melanoma Through the MiR-650/MGMT Axis
Background: Alkylating agents are critical therapeutic options for melanoma, while dacarbazine (DTIC)-based chemotherapy showed poor sensitivity in clinical trials. Long non-coding RNAs (lncRNAs) were highlighted in the progression of malignant tumors in recent years, whereas little was known about...
Autores principales: | Wu, Kai, Wang, Qiang, Liu, Yu-Lin, Xiang, Zhuo, Wang, Qing-Qing, Yin, Li, Liu, Shun-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010678/ https://www.ncbi.nlm.nih.gov/pubmed/33816296 http://dx.doi.org/10.3389/fonc.2021.643613 |
Ejemplares similares
-
LncRNA POU3F3 promotes melanoma cell proliferation by downregulating lncRNA MEG3
por: Liu, Yingnan, et al.
Publicado: (2021) -
LncRNA MCTP1-AS1 Regulates EMT Process in Endometrial Cancer by Targeting the miR-650/SMAD7 Axis
por: Gao, Qin, et al.
Publicado: (2021) -
Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014) -
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
por: Tawbi, H A, et al.
Publicado: (2011) -
LncRNA NEAT1 Promotes Inflammatory Response in Sepsis via the miR-31-5p/POU2F1 Axis
por: Yang, Yang, et al.
Publicado: (2021)